APA

Diletti R., Serruys P. W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H. M. & Chevalier B. (20130107). ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. : American heart journal.

Chicago

Diletti Roberto, Serruys Patrick W, Farooq Vasim, Sudhir Krishnankutty, Dorange Cecile, Miquel-Hebert Karine, Veldhof Susan, Rapoza Richard, Onuma Yoshinobu, Garcia-Garcia Hector M and Chevalier Bernard. 20130107. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. : American heart journal.

Harvard

Diletti R., Serruys P. W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H. M. and Chevalier B. (20130107). ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. : American heart journal.

MLA

Diletti Roberto, Serruys Patrick W, Farooq Vasim, Sudhir Krishnankutty, Dorange Cecile, Miquel-Hebert Karine, Veldhof Susan, Rapoza Richard, Onuma Yoshinobu, Garcia-Garcia Hector M and Chevalier Bernard. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. : American heart journal. 20130107.